Pacira BioSciences (PCRX) Non-Current Assets (2010 - 2026)

Pacira BioSciences' Non-Current Assets history runs 17 years deep, the most recent figure standing at $693.6 million for Q1 2026.

• In Q1 2026, Non-Current Assets fell 16.1% year-over-year to $693.6 million; the TTM figure through Mar 2026 stood at $2.9 billion (down 15.64% YoY), while the FY2025 annual figure was $716.9 million, down 11.31% from the prior year.
• Non-Current Assets was $693.6 million for Q1 2026 at Pacira BioSciences, down from $716.9 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $1.2 billion in Q1 2022 to a low of $693.6 million in Q1 2026.
• Historically, Non-Current Assets has averaged $981.6 million across 5 years, with a median of $1.0 billion in 2024.
• The sharpest annual moves came in 2022 and 2024: Non-Current Assets surged 126.49% in 2022, then slipped 24.05% in 2024.
• A 5-year view of Non-Current Assets shows it stood at $1.2 billion in 2022, then slipped by 10.02% to $1.1 billion in 2023, then declined by 24.05% to $808.4 million in 2024, then slipped by 11.31% to $716.9 million in 2025, then slipped by 3.26% to $693.6 million in 2026.
• The last three Non-Current Assets figures came in at $693.6 million (Q1 2026), $716.9 million (Q4 2025), and $734.8 million (Q3 2025), per Business Quant data.